Siyuan Shen
University of Massachusetts Medical School
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Siyuan Shen.
Vaccine | 2008
Shixia Wang; Jeffrey S. Kennedy; Kim West; David C. Montefiori; Scott Coley; John M. Lawrence; Siyuan Shen; Sharone Green; Alan L. Rothman; Francis A. Ennis; James Arthos; Ranajit Pal; Phillip D. Markham; Shan Lu
An optimally effective AIDS vaccine would likely require the induction of both neutralizing antibody and cell-mediated immune responses, which has proven difficult to obtain in previous clinical trials. Here we report on the induction of Human Immunodeficiency Virus Type-1 (HIV-1)-specific immune responses in healthy adult volunteers that received the multi-gene, polyvalent, DNA prime-protein boost HIV-1 vaccine formulation, DP6-001, in a Phase I clinical trial conducted in healthy adult volunteers of both genders. Robust cross-subtype HIV-1-specific T cell responses were detected in IFNgamma ELISPOT assays. Furthermore, we detected high titer serum antibody responses that recognized a wide range of primary HIV-1 Env antigens and also neutralized pseudotyped viruses that express the primary Env antigens from multiple HIV-1 subtypes. These findings demonstrate that the DNA prime-protein boost approach is an effective immunization method to elicit both humoral and cell-mediated immune responses in humans, and that a polyvalent Env formulation could generate broad immune responses against HIV-1 viruses with diverse genetic backgrounds.
Journal of Virology | 2005
Shixia Wang; James Arthos; John M. Lawrence; Donald Van Ryk; Innocent Mboudjeka; Siyuan Shen; Te-hui W. Chou; David C. Montefiori; Shan Lu
ABSTRACT Strategies are needed for human immunodeficiency virus type 1 vaccine development that improves the neutralizing antibody response against primary isolates of the virus. Here we examined recombinant DNA priming followed by subunit protein boosting as a strategy to generate neutralizing antibodies. Both plasmid-based and recombinant protein envelope (Env) glycoprotein immunogens were derived from a primary viral isolate, JR-FL. Serum from rabbits immunized with either gp120 or gp140 DNA vaccines delivered by gene gun inoculation followed by recombinant gp120 protein boosting was capable of neutralizing JR-FL. Neither the DNA vaccines alone nor the gp120 protein alone generated a detectable neutralizing antibody response against this virus. Neutralizing antibody responses using gp120 DNA and gp140 DNA for priming were similar. The results suggest that Env DNA priming followed by gp120 protein boosting provides an advantage over either approach alone for generating a detectable neutralizing antibody response against primary isolates that are not easily neutralized.
Journal of Medical Primatology | 2005
Ranajit Pal; Shixia Wang; V. S. Kalyanaraman; B.C. Nair; Stephen Whitney; Timothy Keen; Lindsey Hocker; Lauren Hudacik; Nicolas Rose; Anthony D. Cristillo; Innocent Mboudjeka; Siyuan Shen; Te-Hui Wu-Chou; David C. Montefiori; John R. Mascola; Shan Lu; Phillip D. Markham
Abstract: Immunization of macaques with multivalent DNA encoding gp120 genes from HIV‐1 subtypes A, B, C and E and a gag gene followed by boosting with homologous gp120 proteins elicited strong anti‐gp120 antibodies capable of neutralizing homologous and to a lesser degree heterologous HIV‐1 isolates. Both Env‐ and Gag‐specific cell mediated immune (CMI) responses were detected in the immunized animals. Following rectal challenge with an SHIV isolate encoding HIV‐1Ba‐Lenv, plasma viremia in the infected immunized animals was significantly lower than that observed in the naïve animals. Further, one of six immunized animals was completely protected whereas all six naïve animals were infected. These results demonstrate that a vaccine based on priming with a polyvalent DNA vaccine from multiple HIV‐1 subtypes followed by boosting with homologous Env proteins elicits anti‐HIV‐1 immune responses capable of controlling rectal transmission of SHIVBa‐L.
Journal of Virology | 2005
Simone Spaderna; Barbara Kropff; Yvonne Ködel; Siyuan Shen; Scott Coley; Shan Lu; William J. Britt; Michael Mach
ABSTRACT The coding capacity of human cytomegalovirus (HCMV) for glycoproteins by far exceeds that of other herpesviruses. Few of these proteins have been characterized so far. We have investigated the gene product of reading frame UL132. The putative protein product of UL132 is a glycoprotein with a theoretical mass of 29.8 kDa. Transcription analysis revealed that the gene is transcribed with a true late kinetics from the laboratory-adapted strain AD169 and the low-passage isolate TB40E. Two proteins of 22 to 28 kDa and 45 to 60 kDa were detected in virus-infected cells as well as in extracellular virions. The larger protein carried N-linked carbohydrates. Both protein forms were present in laboratory-adapted strains as well as in low-passage isolates of HCMV. Recombinant viruses with the UL132 gene deleted were constructed in the low-passage HCMV isolate PAN as well as the high-passage isolate AD169. Deletion of UL132 from either genome resulted in a pronounced replication deficit with a reduction of approximately 100-fold for HCMV strain AD169. Thus, the protein product of the UL132 reading frame represents a structural viral glycoprotein of HCMV that has an important function for viral replication in tissue culture.
Human Vaccines & Immunotherapeutics | 2013
Anna Gil; Siyuan Shen; Scott Coley; Laura Gibson; Don J. Diamond; Shixia Wang; Shan Lu
As a leading cause of congenital infection and a major threat to immunocompromised individuals, human cytomegalovirus (HCMV) is a major global public health concern. Effective HCMV vaccines would need to induce potent and balanced humoral and cellular immune responses. In this pilot study, immunogenicity studies were conducted in mice to examine HCMV antigen-specific antibody and T cell responses when a heterologous prime-boost immunization strategy was tested. DNA vaccines expressing either targets of protective antibody responses (gB and gM/gN) or well characterized T cell immunogens (pp65, pp150, and IE1) were used as the priming immunization while the live attenuated HCMV vaccine Towne strain was used as the boost, which may act like an inactivated vaccine due to the inability of HCMV to replicate in a mouse host. Our data indicate that while DNA vaccines were effective in priming HCMV-specific antibody responses, the final titers of gB- or gM-specific antibodies were not much different from those elicited by using multiple immunizations of HCMV alone. In contrast, DNA priming significantly enhanced T cell responses against gB, pp65, and IE1 as measured by IFN-γ. However, HCMV alone was not effective in eliciting strong T cell immune responses when used in a mouse host. Our data indicate that the complexity of antigen composition from a large virus, such as HCMV, may affect the profile of immune responses when viral vaccines are used as a boost.
Current HIV Research | 2008
Zuhu Huang; Arthur Chou; Jonathan Tanguay; Siyuan Shen; Innocent Mboudjeka; Te-Hui Chou; Shan Lu; Shixia Wang
A good understanding about the structure and function of the envelope glycoprotein (Env) from primary human immunodeficiency virus-1 (HIV-1) isolates is important in facilitating the development of effective neutralizing antibody responses as a component of an effective HIV-1 vaccine. In the current study, the antigenicity of a panel of diverse HIV-1 primary Env from different clades of HIV-1 Group M was analyzed using rabbit sera produced by either 3- or 9-valent gp120 DNA vaccine formulations. Both the 3- and 9-valent gp120 DNA vaccine formulations elicited HIV-1 gp120-specific antibodies in immunized rabbits. However, we observed two levels of primary envelope antigenicity to the same set of rabbit immune sera and that the level of glycosylation, particularly in the V1 loop, may contribute to such diversity. Bioinformatics analysis on the distribution and average number of the N-linked glycosylation sites in all variable regions (V1-V5) was conducted. A linear plot demonstrated that the average number of potential N-glycosylation sites in the V1 and V4 loops correlates to the size of the loop. These data provide further evidence on the complexity of primary HIV-1 Env antigens and offers new insight into the mechanisms that HIV-1 uses to escape protective immune responses.
Virology | 2006
Shixia Wang; Ranajit Pal; John R. Mascola; Te-hui W. Chou; Innocent Mboudjeka; Siyuan Shen; Qin Liu; Stephen Whitney; Timothy Keen; B.C. Nair; V. S. Kalyanaraman; Philip Markham; Shan Lu
Vaccine | 2006
Shixia Wang; Diego J. Farfán-Arribas; Siyuan Shen; Te-hui W. Chou; Allison Hirsch; Feng He; Shan Lu
Virology | 2006
Ranajit Pal; Shixia Wang; V. S. Kalyanaraman; B.C. Nair; Stephen Whitney; Timothy Keen; Lindsey Hocker; Lauren Hudacik; Nicolas Rose; Innocent Mboudjeka; Siyuan Shen; Te-Hui Wu-Chou; David C. Montefiori; John R. Mascola; Phillip D. Markham; Shan Lu
Virology | 2006
Anthony D. Cristillo; Shixia Wang; Michael S. Caskey; Tami Unangst; Lindsey Hocker; Leilei He; Lauren Hudacik; Stephen Whitney; Tim Keen; Te-hui W. Chou; Siyuan Shen; Swati Joshi; V. S. Kalyanaraman; B.C. Nair; Phillip D. Markham; Shan Lu; Ranajit Pal
Collaboration
Dive into the Siyuan Shen's collaboration.
Henry M. Jackson Foundation for the Advancement of Military Medicine
View shared research outputs